Top Stories
The life and death of the guitarist’s guitarist, Roy Buchanan
- Roy Buchanan inspired Jeff Beck, Gary Moore and Joe Bonamassa, but suffered a life of addiction and died a bluesman’s death
- Beaver County Times
Scott Tady: Beaver County singer tours Left Coast, zombies invade Rochester
Albums
More Stories
- EntertainmentGuitar World
“Playing with Bob Dylan was like entering The Twilight Zone of music. You thought, ‘They’re going to wake me up tomorrow because all of this is impossible’”: Robbie Robertson reflects on his remarkabl
In his final Guitar World interview, the late guitar legend shares his earliest guitar influences, what it was like to get booed onstage with Dylan and why the Band’s final days were so heartbreaking
- LifestyleGuitar World
Blues guitar techniques you can learn from Telecaster master Roy Buchanan
Take a deep dive into the style of one of the best players to have ever picked up a Telecaster, in a lesson that will whip your hybrid picking chops into shape in no time
- EntertainmentGuitar World
Watch Lonnie Mack, one of the original Flying V masters, trade licks with Tele titans Albert Collins and Roy Buchanan
The three six-string aces came together for the aptly named American Guitar Heroes concert at Carnegie Hall in 1985
- CelebrityGuitar World
How Jeff Beck and Seymour Duncan created humbucker magic with the classic JB pickup
While the classic Seymour Duncan SH-4 JB was never actually a signature pickup, without Jeff it may never have happened…
- BusinessMotley Fool
Why Dynavax Stock Popped by Over 5% Today
A positive analyst take on Dynavax Technologies' (NASDAQ: DVAX) stock lit the biotech company's shares on fire Tuesday. The enthusiastic analyst is JMP Securities' Roy Buchanan, who initiated coverage on Dynavax stock early Tuesday morning. Buchanan's recommendation is market outperform (buy, in other words) at a price target of $22 per share.
- News24/7 Wall St.
Can Geron Shares Still Ultimately Double?
A research report from Janney's Roy Buchanan issued on Friday included a fair value estimate for Geron shares that was more than 100% above the share price of the time.
- NewsBenzinga
Janney Analyst Starts Clovis Oncology At Buy, Expects Regulatory Approvals Coming In 2016
The share price of Clovis Oncology Inc (NASDAQ: CLVS ) has appreciated 7.57 percent in the last month, after having fallen 70.08 percent over the past three months. Janney’s Roy Buchanan has initiated ...
- NewsSeeking Alpha (Transcripts)
Corcept Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Corcept Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
- EntertainmentBillboard
VARIOUS ARTISTS: “ALLIGATOR RECORDS 40TH ANNIVERSARY COLLECTION”
Properly chronicling the history of a long-lived label is a tricky prospect and usually requires a substantial boxed set.
